On 30 November, Nevro announced that it has signed and closed a deal to pay $40m at closing to acquire Pennsylvania-based Vyrsa.

Nevro also agreed to pay up to $35m in cash or stock based on the achievement of certain sales and development milestones. (Also see "News We’re Watching: New AF Guidelines, Nevro Buys Vyrsa, LivaNova Responds To Cyberattack" - Medtech Insight, 5 December, 2023.)

Vyrsa claims to be the only company to offer a complete line of state-of-the-art SI joint fusion devices cleared by the US Food and Drug Administration. Its products include the V1 SI fusion implant with integrated lateral transfixation, the Pro cortical allograft, and the Siconus lateral screws.

These devices are compatible with a hybrid approach to SI fusion that promotes bone fusion and compression of the joint space.

“We’re A Pain-Management Company.” Nevro Adds SI Joint Surgery To SCS Business

More from Deals

More from Business